Effect of Teriparatide on Unstable Pertrochanteric Fractures
Table 4
Outcome measures of patients in the control and teriparatide subgroups at the last follow-up.
Parameters
AO-OTA A2.1
AO-OTA A2.2
AO-OTA A2.3
Group A
Group B
Group A
Group B
Group A
Group B
= 9
= 6
= 32
= 18
= 3
= 5
Union time (weeks)
14.1 ± 2.3
10.5 ± 2.4*
15.3 ± 2.0
11.8 ± 2.7*
14.6 ± 2.1
11.4 ± 2.0*
Tip apex distance (mm)
18.8 ± 2.6
18.6 ± 2.6
18.7 ± 2.5
18.3 ± 2.0
19.1 ± 2.4
18.8 ± 2.1
Sliding of lag screw (mm)
7.8 ± 3.2
3.2 ± 1.9*
9.9 ± 4.9
4.8 ± 2.7*
10.1 ± 6.2
4.4 ± 3.7*
Femoral shortening (mm)
9.1 ± 4.8
4.6 ± 3.1*
13.6 ± 8.6
5.2 ± 2.9*
16.1 ± 8.7
7.2 ± 5.2*
Varus collapse (degrees)
5.9 ± 3.1
2.4 ± 1.3*
7.6 ± 4.7
3.7 ± 2.6*
8.7 ± 6.1
2.6 ± 1.6*
Group A: patient without any supplementation of pharmacologic treatment. Group B: patient treated with teriparatide. Values are shown as mean ± standard deviation. values for between-group comparisons were determined by Student’s -test which was used for parametric variables. *Statistically significant ( value < 0.05).
